SRR934921
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 3.1865965834428382
- age_years
- 74
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.685
- INTERFERON_GAMMA_RESPONSE+0.657
- IL6_JAK_STAT3_SIGNALING+0.627
- TNFA_SIGNALING_VIA_NFKB+0.611
- MTORC1_SIGNALING+0.562
- INFLAMMATORY_RESPONSE+0.561
- PROTEIN_SECRETION+0.546
- ALLOGRAFT_REJECTION+0.528
- TGF_BETA_SIGNALING+0.523
- MYC_TARGETS_V1+0.522
Top 10 suppressed
- KRAS_SIGNALING_DN-0.501
- SPERMATOGENESIS-0.327
- PANCREAS_BETA_CELLS-0.237
- MYOGENESIS-0.112
- HEDGEHOG_SIGNALING-0.109
- APICAL_SURFACE-0.071
- WNT_BETA_CATENIN_SIGNALING+0.013
- ESTROGEN_RESPONSE_LATE+0.076
- BILE_ACID_METABOLISM+0.088
- ESTROGEN_RESPONSE_EARLY+0.088
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 9BFF7746-9003-4941-9590-0B813E00B326 | — | — | 0.980 |
| 2 | SRR934913 | — | — | 0.977 |
| 3 | DE370889-1057-4355-AFD8-CCFCDC6CD00F | — | — | 0.974 |
| 4 | 0E5EDC5A-5AD4-499E-8777-CA6B6F63307F | — | — | 0.974 |
| 5 | 7876A884-F031-42AB-ADC0-89589760FB6B | — | — | 0.974 |
| 6 | AA762299-102B-4E35-B4A5-A94A122EF9DB | — | — | 0.971 |
| 7 | SRR934897 | — | — | 0.971 |
| 8 | 0E66EFB0-712B-4A52-8F75-A37F030CABEF | — | — | 0.971 |
| 9 | 228C2042-804C-47FA-B565-1993E1015D40 | — | — | 0.971 |
| 10 | E9FC1686-028B-476C-B51B-4956213D874B | — | — | 0.970 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 44 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.685 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.657 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.627 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.611 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.562 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.561 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.546 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.528 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.523 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.522 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.520 | Inavolisib | — uncovered |
| APOPTOSIS | 0.503 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.502 | Inavolisib | — uncovered |
| COMPLEMENT | 0.498 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.492 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.482 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.459 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.457 | Inavolisib | — uncovered |
| HYPOXIA | 0.447 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.447 | Idelalisib | — uncovered |